No Data
Anke Biotech: 2024 Semi-Annual Report
Anke Biotech: 2024 Semi-Annual Report Summary
Anhui Anke Biotechnology (300009.SZ): The net income in the first half of the year was 0.416 billion yuan, a year-on-year increase of 4.99%.
Anhui Anke Biotechnology (300009.SZ) released its semi-annual report for 2024, with a total operating revenue of 1.299 billion yuan during the reporting period, a year-on-year increase of 0.90%; a net income attributable to shareholders of listed companies of 0.416 billion yuan, a year-on-year increase of 4.99%; a net income attributable to shareholders of listed companies after deducting non-recurring gains and losses of 0.39 billion yuan, a year-on-year increase of 1.86%; and earnings per share of 0.2482 yuan.
Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Individual Investors Are Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Biggest Owners and Were Hit After Market Cap Dropped CN¥686m
Anhui Anke Biotechnology (300009.SZ): Acetaminophen raw materials have received approval notices for listing applications.
On July 24th, Gelunhui reported that Anhui Anke Biotechnology (300009.SZ) announced that its wholly-owned subsidiary, Shanghai Suhao Yiming Pharmaceutical Co., Ltd., received the Approval Notice for the Marketing of Chemical Pharmaceutical Active Ingredients for Acetate Degarelix issued by the National Medical Products Administration and was publicly announced on the official website of the Medical Products Evaluation Center of the National Medical Products Administration. The joint approval result with the preparation is A, indicating that the API has met the qualification for market access in China. Acetate degarelix is a synthetic decapeptide, a gonadotropin-releasing hormone (GnRH) antagonist, which can competitively bind to pituitary cell membrane receptors with endogenous GnRH to inhibit its release.
Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE:300009) Looks Inexpensive But Perhaps Not Attractive EnoughNo Data
No Data
